AstraZeneca PLC Director/PDMR Shareholding
November 15 2024 - 4:00AM
RNS Regulatory News
RNS Number : 4232M
AstraZeneca PLC
15 November 2024
15 November 2024 10:00
GMT
Transaction by Person
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company)
announces that it was notified on 14 November 2024 that Pascal
Soriot, Chief Executive Officer, purchased 20,000 of the Company's
ordinary shares of $0.25 each (Ordinary Shares) on 14 November
2024, as set out below.
|
PDMR
|
Position
|
Nature of
the transaction
|
Quantity
|
Price
|
|
Pascal
Soriot
|
Chief
Executive Officer
|
Purchase
of Ordinary Shares
|
20,000
|
GB£102.03
|
Further details are set out in the
attached notification, made in accordance with the requirements of
the EU Market Abuse Regulation (since it forms part of UK law
pursuant to the European Union (Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Purchase of AstraZeneca PLC Ordinary
Shares of US$0.25
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£102.03
|
20,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
14 November 2024
|
|
f)
|
Place of the transaction
|
LON
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUVOWRSSUAARA
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Nov 2023 to Nov 2024
